Category Archives: TRIPS

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

June 2017 Alert: Pressure on countries hiked by US on IP

The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include India, Indonesia, China, Thailand, Ukraine in Asia … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

TRIPS Council Members: Defining IP Rights And The Public Interest

Source: IPWatch “Political and economic pressure placed on governments to forgo the use of TRIPS flexibilities violates the integrity and legitimacy of the system of legal duties and rights created by the TRIPS agreement and as reaffirmed by the Doha … Continue reading

Posted in Compulsory Licensing, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

FOIFOIA documents. In 2015 Novartis asked U.S. Dept of Commerce to Pressure Colombia Against Compulsory License on Glivec

In February 2016, KEI submitted a FOIA to USTR requesting “all correspondence and notes sent internally by the Office of the US Trade Representative as well as with Colombian government officials, other foreign government officials, and non-governmental persons or entities … Continue reading

Posted in Compulsory Licensing, Uncategorized | Leave a comment

TRIPS Council Members: Defining IP Rights And The Public Interest

Source: IP Watch 15/06/2017 BY CATHERINE SAEZ, INTELLECTUAL PROPERTY WATCH “Political and economic pressure placed on governments to forgo the use of TRIPS flexibilities violates the integrity and legitimacy of the system of legal duties and rights created by the … Continue reading

Posted in Compulsory Licensing, Doha Declaration, HIV/Aids, TRIPS, US pressure on India | Leave a comment

MSF criticizes Swiss pharma aims at upcoming India-EFTA trade talks

Source: Pharma Letter On May 30, 2017 (tomorrow), trade talks will resume for the India-EFTA (European Free Trade Association) free trade agreement (FTA) in Liechtenstein, between India and the EFTA countries of Switzerland, Norway, Iceland and Liechtenstein. Through this deal, … Continue reading

Posted in EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment

Unlikely Alliance Of India, US Could Keep Medicines Access On WHO Agenda

BY CATHERINE SAEZ, INTELLECTUAL PROPERTY WATCH It is not often that on the matter of access to medicines, India and the United States agree at the World Health Organization. But the issue of access to medicines is rising on the … Continue reading

Posted in TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment